Source: Eur Respir J, 57 (1) 2001120; 10.1183/13993003.01120-2020
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Meindina G. Haarman, Marilyne Lévy, Marcus T.R. Roofthooft, Johannes M. Douwes, Theresia R. Vissia-Kazemier, Isabelle Szezepanski, Rolf M.F. Berger, Damien Bonnet. Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension. Eur Respir J, 57 (1) 2001120; 10.1183/13993003.01120-2020

Member's Comments

No comment yet.

Related content which might interest you: Initial dual oral combination therapy in pulmonary arterial hypertension Source: Eur Respir J 2016; 47:1727-1736 Year: 2016 Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study Source: Eur Respir J 2014; 43: 1691-1697 Year: 2014 Response to exercise in patients with pulmonary arterial hypertension treated with combination therapy Source: ERJ Open Res, 7 (1) 00725-2020; 10.1183/23120541.00725-2020 Year: 2021 The role of combination therapy in managing pulmonary arterial hypertension Source: Eur Respir Rev 2014; 23: 469-475 Year: 2014 Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Successful pregnancy outcome in patients with pulmonary arterial hypertension receiving prostayclin therapy Source: Annual Congress 2004 - Pulmonary hypertension Year: 2004 Beyond a single pathway: combination therapy in pulmonary arterial hypertension Source: Eur Respir Rev 2016; 25: 408-417 Year: 2016 Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension Source: Eur Respir J 2016; 48: 1514-1516 Year: 2016 Optimal management of severe pulmonary arterial hypertension Source: Eur Respir Rev 2011; 20: 254-261 Year: 2011 Challenges in the diagnosis and treatment of pulmonary arterial hypertension Source: Eur Respir Rev 2012 21: 313-320 Year: 2012 Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Combined treatment in pulmonary hypertension Source: International Congress 2016 – GR3 Scientific Grand Round: precision medicine Year: 2016 Dipyridamol as adjuvant therapy in patients with pulmonary arterial hypertension (PAH) Source: Eur Respir J 2005; 26: Suppl. 49, 562s Year: 2005 Pulmonary arterial hypertension: combination therapy in the modern management era Source: Eur Respir Rev 2010 19: 348-349 Year: 2010 Combination therapy with sildenafil and sitaxentan therapy for pulmonary arterial hypertension Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous Year: 2008 Upfront combination therapy in the treatment of scleroderma-associated pulmonary arterial hypertension: Results of an open label trial Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Double combination therapy in patients with pulmonary arterial hypertension associated with congenital heart defects Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Treatment options for paediatric pulmonary arterial hypertension Source: Eur Respir Rev 2010 19: 321-330 Year: 2010 General and standard therapy of pulmonary arterial hypertension Source: International Congress 2017 – Russian Programme 2017 Year: 2017 Real-life data on the medical therapy of pulmonary arterial and chronic thromboembolic pulmonary hypertension Source: International Congress 2017 – PAH and CTEPH Year: 2017